MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
0.4512
-0.0394
-8.03%
Opening 14:58 06/25 EDT
OPEN
0.4908
PREV CLOSE
0.4906
HIGH
0.5190
LOW
0.4511
VOLUME
212.63K
TURNOVER
--
52 WEEK HIGH
7.19
52 WEEK LOW
0.4200
MARKET CAP
12.64M
P/E (TTM)
-0.1399
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JSPR last week (0615-0619)?
Weekly Report · 3d ago
Jasper Therapeutics announces annual shareholder meeting
PUBT · 06/15 20:04
Weekly Report: what happened at JSPR last week (0608-0612)?
Weekly Report · 06/15 09:47
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice
TipRanks · 06/09 20:53
Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3
Benzinga · 06/09 20:10
JASPER THERAPEUTICS - ON JUNE 3, 2026, CO RECEIVES NASDAQ NOTICE FOR MINIMUM BID PRICE NON-COMPLIANCE - SEC FILING
Reuters · 06/09 20:07
Jasper Therapeutics gets Nasdaq notice after shares trade below $1 bid-price minimum
PUBT · 06/09 20:07
Weekly Report: what happened at JSPR last week (0601-0605)?
Weekly Report · 06/08 09:44
More
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.